Recognizing that developmental research funds are an integral part of the SPORE, we commit $175,000 peryear to these endeavors. This represents a significant percent in the budget of the UMCCC ProstateSPORE and reflects the continued commitment of this program to the development of innovativetranslational research in prostate cancer. The focus of the Developmental Research Program is to provideinvestigators the ability to generate data that would become the preliminary data for an R01 grant applicationor an equivalent proposal. Investigators from outside the field of prostate cancer are encouraged to applythrough campus wide announcements as well as through personal interactions with the SPOREinvestigators. We developed a stepwise proposal solicitation and review process for pilot projects utilizing aNIH-type PHS 398 format that has been streamlined for rapid turn around of research proposals and whichrecognizes that these projects may have little preliminary data. Investigators may apply for pilot projectgrants ($40,000 - $50,000 per year) or seed grants ($5,000 - $10,000 per year). Since 1995 we have funded52 pilot projects and 61 seed grants with a total investment of $2.5 million. This has resulted in over $20million in subsequent grants and 101 manuscripts. Dr. Maha Hussain and Dr. Mark Day serve as Co-Directors for the Developmental Research Program. Dr. Hussain is a Professor of Internal Medicine andUrology, and is nationally and internationally recognized for her scientific clinical research expertise in thearea of genitourinary-oncology, particularly prostate and bladder cancers. She serves as the 'clinical' expertfor the Research Development Program. Dr. Mark'Day is a Professor of Urology and has publishedextensively in the area of prostate cell biology. He serves as the 'basic science' mentor of the ResearchDevelopment Program. Dr. Day is the PI of the Urology Training Grant and participates as a mentor in theCancer Biology Training Grant. Drs. Hussain and Day meet twice with each project investigator to reviewprogress. Project investigators also take part in the monthly SPORE meetings and annual retreat.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
2P50CA069568-11
Application #
7468650
Study Section
Special Emphasis Panel (ZCA1-RPRB-M (J1))
Project Start
2008-06-01
Project End
2013-05-31
Budget Start
2008-06-01
Budget End
2009-05-31
Support Year
11
Fiscal Year
2008
Total Cost
$71,788
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
073133571
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Rye, Morten Beck; Bertilsson, Helena; Andersen, Maria K et al. (2018) Cholesterol synthesis pathway genes in prostate cancer are transcriptionally downregulated when tissue confounding is minimized. BMC Cancer 18:478
Xie, Yuanyuan; Cao, Zhen; Wong, Elissa Wp et al. (2018) COP1/DET1/ETS axis regulates ERK transcriptome and sensitivity to MAPK inhibitors. J Clin Invest 128:1442-1457
Singhal, Udit; Wang, Yugang; Henderson, James et al. (2018) Multigene Profiling of CTCs in mCRPC Identifies a Clinically Relevant Prognostic Signature. Mol Cancer Res 16:643-654
Wang, Xiaoju; Qiao, Yuanyuan; Asangani, Irfan A et al. (2017) Development of Peptidomimetic Inhibitors of the ERG Gene Fusion Product in Prostate Cancer. Cancer Cell 31:532-548.e7
Blattner, Mirjam; Liu, Deli; Robinson, Brian D et al. (2017) SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling. Cancer Cell 31:436-451
Dai, Xiangpeng; Gan, Wenjian; Li, Xiaoning et al. (2017) Prostate cancer-associated SPOP mutations confer resistance to BET inhibitors through stabilization of BRD4. Nat Med 23:1063-1071
Lin, Ke-Chih; Torga, Gonzalo; Wu, Amy et al. (2017) Epithelial and mesenchymal prostate cancer cell population dynamics on a complex drug landscape. Converg Sci Phys Oncol 3:
Piert, Morand; Montgomery, Jeffrey; Kunju, Lakshmi Priya et al. (2016) 18F-Choline PET/MRI: The Additional Value of PET for MRI-Guided Transrectal Prostate Biopsies. J Nucl Med 57:1065-70
Van Allen, Eliezer M; Robinson, Dan; Morrissey, Colm et al. (2016) A comparative assessment of clinical whole exome and transcriptome profiling across sequencing centers: implications for precision cancer medicine. Oncotarget 7:52888-52899
Mehra, Rohit; Udager, Aaron M; Ahearn, Thomas U et al. (2016) Overexpression of the Long Non-coding RNA SChLAP1 Independently Predicts Lethal Prostate Cancer. Eur Urol 70:549-552

Showing the most recent 10 out of 527 publications